Form 4: Centene Director Christopher Coughlin Reports Acquisition of Common Stock

Director Christopher Coughlin reported acquiring 452 shares of Centene Corp common stock on June 30, 2024.

Summary

• On June 30, 2024, Christopher Coughlin, a director of Centene Corp, acquired 452 shares of common stock.
• The acquisition was made at a price of $0 per share.
• Following the transaction, Coughlin's direct ownership increased to 25,955.926 shares of common stock, which includes 2,916 shares of restricted stock units subject to vesting requirements.
• Coughlin also holds options to purchase 10,000 shares of Centene common stock at an exercise price of $80.57, exercisable from February 7, 2025, to February 7, 2032.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard regulatory filing. The acquisition itself could be seen as slightly positive, but without more context, it's difficult to gauge the overall impact.

Positives

• The director's acquisition of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The filing does not contain specific forward-looking statements, but the director's continued holdings suggest a long-term interest in Centene's performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. Monitoring these filings can offer insights into management's sentiment and potential future actions.

Comparison to Industry Standards

• Comparing Coughlin's holdings and transactions to those of other directors in similar healthcare companies (e.g., UnitedHealth Group, CVS Health) can provide context on the scale of his investment.
• Analyzing the timing of these transactions relative to Centene's performance and industry trends can offer insights into potential motivations.
• Benchmarking the vesting schedules of Coughlin's restricted stock units against industry norms can reveal information about the company's compensation practices.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a company director.

Key Dates